Johnson Johnson Stock Today

JNJ Stock  USD 155.40  0.88  0.57%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 3

 
High
 
Low
Very Low
Johnson Johnson is selling for 155.40 as of the 28th of November 2024. This is a 0.57% increase since the beginning of the trading day. The stock's last reported lowest price was 154.6. Johnson Johnson has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on November 15, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Johnson Johnson's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of September 1944
Category
Healthcare
Classification
Health Care
Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 2.41 B outstanding shares of which 17.48 M shares are currently shorted by investors with about 2.54 days to cover. More on Johnson Johnson

Moving together with Johnson Stock

  0.78VALN Valneva SE ADRPairCorr
  0.71FDMT 4D Molecular TherapeuticsPairCorr
  0.85LLY Eli Lilly Sell-off TrendPairCorr
  0.87MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr

Moving against Johnson Stock

  0.87BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.82NAMS NewAmsterdam PharmaPairCorr
  0.74GILD Gilead SciencesPairCorr
  0.5PMVP Pmv PharmaceuticalsPairCorr
  0.41LPCN LipocinePairCorr
  0.32ESLAW Estrella ImmunopharmaPairCorr

Johnson Stock Highlights

ESG Sustainability
Environmental
Governance
Social
ChairmanAlex Gorsky
Thematic Ideas
Showing 3 out of 5 themes
Old NameJohnson & Johnson
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Dow Jones Industrial, NYSE Composite, NYSE 100 Index, ARCA Major Markets, SP 500 Index, ARCA Institutional, Nasdaq CTA Artificial, ARCA Pharmaceutical, BTRINVSTNG 100 INDEX, BETTERINVESTING 100 INDEX, SP 100, Dividend Beast, Baby Boomer Prospects, Corona Opportunity, Compulsion, Investor Favorites, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal TestingCatholic
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Assets0.140.2098
Way Down
Pretty Stable
Asset Turnover0.910.5082
Way Up
Pretty Stable
Gross Profit Margin0.770.6882
Moderately Up
Pretty Stable
Total Current Liabilities48.6 B46.3 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total55.1 B52.5 B
Sufficiently Up
Slightly volatile
Total Assets175.9 B167.6 B
Sufficiently Up
Slightly volatile
Total Current Assets31.1 B53.5 B
Way Down
Pretty Stable
Total Cash From Operating Activities13.5 B22.8 B
Way Down
Slightly volatile
Debt Levels
Johnson Johnson can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Johnson Johnson's financial leverage. It provides some insight into what part of Johnson Johnson's total assets is financed by creditors.
Liquidity
Johnson Johnson has 29.33 B in debt with debt to equity (D/E) ratio of 0.43, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.4, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for Johnson to invest in growth at high rates of return.

Change In Working Capital

2.63 Billion
Johnson Johnson (JNJ) is traded on New York Stock Exchange in USA. It is located in One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 and employs 131,900 people. Johnson Johnson is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 372.03 B. Johnson Johnson runs under Pharmaceuticals sector within Health Care industry. The entity has 2.41 B outstanding shares of which 17.48 M shares are currently shorted by investors with about 2.54 days to cover. Johnson Johnson has about 5.37 B in cash with 22.79 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.03.
Check Johnson Johnson Probability Of Bankruptcy
Ownership Allocation
Johnson Johnson has a total of 2.41 Billion outstanding shares. The majority of Johnson Johnson outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Johnson Johnson to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Johnson Johnson. Please pay attention to any change in the institutional holdings of Johnson Johnson as this could imply that something significant has changed or is about to change at the company. Please note that on November 15, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Johnson Johnson's common stock.
Check Johnson Ownership Details

Johnson Stock Institutional Holders

InstituionRecorded OnShares
Bank Of America Corp2024-06-30
24.5 M
Legal & General Group Plc2024-06-30
23.3 M
Bank Of New York Mellon Corp2024-06-30
21.7 M
Massachusetts Financial Services Company2024-09-30
18.6 M
Fmr Inc2024-09-30
18.3 M
Wells Fargo & Co2024-06-30
18.1 M
Charles Schwab Investment Management Inc2024-09-30
17.6 M
Franklin Resources Inc2024-09-30
16.8 M
Amvescap Plc.2024-06-30
16.7 M
Vanguard Group Inc2024-09-30
231 M
Blackrock Inc2024-06-30
198.2 M
View Johnson Johnson Diagnostics

Johnson Johnson Historical Income Statement

At this time, Johnson Johnson's Income Tax Expense is relatively stable compared to the past year. Net Income From Continuing Ops is expected to hike to about 14.8 B this year, although the value of Other Operating Expenses will most likely fall to nearly 36.9 B. View More Fundamentals

Johnson Stock Against Markets

Johnson Johnson Corporate Directors

Jennifer DoudnaIndependent DirectorProfile
Marillyn HewsonIndependent DirectorProfile
Mary BeckerleIndependent DirectorProfile
Darius AdamczykIndependent DirectorProfile
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.89)
Dividend Share
4.86
Earnings Share
6.06
Revenue Per Share
36.428
Quarterly Revenue Growth
0.052
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.